Battered by an FDA rejection and a string of clinical setbacks, Biohaven Ltd. (BHVN) had been relegated to deep-discount territory. That narrative is beginning to shift.
On Monday, Canaccord Genuity analyst Sumant Kulkarni launched coverage of the clinical-stage neuroscience biotech with a “Buy” rating and a $21 price target—implying more than 100% upside even after the stock jumped over 10% on the news. Biohaven closed the session up 10.36%.
The bullish call follows a regulatory filing last month showing that Sarissa Capital Management, an activist hedge fund known for reshaping biotech portfolios, initiated a 513,184-share position in the fourth quarter. The stake was valued at roughly $5.79 million at quarter-end, accounting for 2.6% of the firm’s disclosed U.S. equity assets.
From a triple-digit price target to a quiet hedge-fund entry, the question is clear: What catalyst are institutions seeing now that the market previously missed?
Kulkarni’s thesis rests squarely on opakalim, Biohaven’s Phase 3 candidate for focal epilepsy. The drug is also being evaluated for inherited erythromelalgia, a rare chronic pain condition. In his view, Biohaven represents an option on the upcoming topline readout, expected in the second half of this year.
Should the data prove positive, the company would pivot from a restructuring story weighed down by past failures to a late-stage asset approaching potential commercialization. That binary outcome underpins Canaccord’s aggressive price target and frames the current window as a tactical entry point.
Beyond epilepsy, Biohaven’s Phase 2 obesity candidate offers institutions a secondary layer of upside. Enrollment is complete, and data are expected in the second half of 2026. While the GLP-1 field is crowded, any differentiated mechanism or cleaner safety profile could carve out meaningful value in a market that continues to expand.
Sarissa Capital’s involvement adds weight to the thesis. The fund has a history of pushing for strategic focus at biotech firms, and its stake suggests conviction that Biohaven’s streamlined, post-restructuring pipeline is not yet reflected in the current valuation.
For clinical-stage biotechs, the cash runway is often the deciding variable. Biohaven ended 2025 with approximately $322 million in cash and subsequently raised another $178.9 million early this year. Management has narrowed its focus to the degrader platform and the obesity candidate, tightening spending while preserving a path to the critical readouts ahead.
Biohaven remains a high-risk proposition. The Phase 3 epilepsy data and Phase 2 obesity results are binary events; either could reverse the recent optimism in a single trading session. Analyst targets and fund filings do not substitute for clinical data.
Yet the market’s logic is evolving. From Sarissa’s fourth-quarter entry to Canaccord’s double-your-money call, institutions are signaling that Biohaven is no longer defined by its prior failures. It has become a “reset” story—armed with a clear catalyst calendar and enough cash to see it through.
The second half of this year, anchored by opakalim’s topline readout, will determine whether that reset sticks. Until then, the tug-of-war over Biohaven is only beginning.
